A Scorpion’s Poison Antivenin R&D+i Project Case from a Mexican Public University – Results and Lessons Learned from the Presented Case

Following the description above we can identify up to 5 clearly defined stages grouped in two phases for the innovation project. At the first phase of the pharmaceutical technological product development it has: Stage 1 Basic Research, Stage 2 Applied Research, Stage 3 Product Development and Local Market launch; on the second phase of production it has: Stage 4 Overseas Market Development, finally Stage 5 USA and FDA approval for Anascorp antivenin.
Undoubtedly behind the project success there are some clearly defined factors, which are: (a) an extraordinary R&D group developed the basic science and technology knowledge; (b) reliable negotiations were done to form the consortium UNAM’s BTI, Silanes/Bioclon through the technology transfer; (c) coo-participation of UNAM and Bioclon researchers to develop the final product, (d) effective intellectual property strategy aligned with business strategy, (e) continuous and permanent R&D works done by researchers of both allied organizations to improve their actual antivenin products and to develop new Fabotherapy products against vipers, snakes and spiders; (f) significant efforts to help sting victims from other countries to get healed going over the border and overseas thus extending its market as a result.
Table 1 shows a summary of different innovation project stages key issues, including project milestones and its results. At Figure 1 it is presented the innovation road map for the entire project’s life cycle.
R&D public university institutes and centres typically operate in base of projects. Sometimes University allies with external public or private organizations to develop technology and the products obtained are industrially scaled to be launch to the market, driving the project to get the upper innovation level (R&D+i).
Compared with the UNAM’s Mexican technology development projects average, we qualify the R&D+i University Alacramyn’s antivenin as an excellent innovation project.

Table 1. lacramyn Project Stages & Milestones

Product Technology Development
Project results and key issues Stage 1UNAM’s



Milestone 1-2UNAM-Silanes Collaboration and TT Agreement Stage 2UNAM’s Applied Research Milestone 3Bioclon



Stage 3Silanes-Bioclon-UNAM product development




UNAM’s Biotechnology Institute TTO Alejandro Alagon Cano JorgePaniagua Possanni-Alagon/Paniagua
Location UNAM’sCellular UNAM’s Scientific Research Coordination UNAM’sBiotechnology Amores St. Col. del Valle, Bioclon’s installations in Mexico City
PhysiologyInstitute Institute Mex City
Timerequired/Date ~ 15 years (1970-1985 ~ 1.5 years/1980 ~ 10 years, 1990 ~ 5 years
Investment(estimated) ~ 1 MUSD per year Not available (NA) ~ 1 MUSD per year NA ~ 2 MUSD per year
Formation of human resources PhD, MSc, Eng Not applicable (NA) PhD, MSc, Eng PhD, MSc, Eng PhD, MSc, Eng
Knowledge Prod. Intl. Art. (Scopus) Possani, Alagon  Development and neg. of Collaboration and Technology Transfer Contract Possani, Alagon International and national articles Possani, Alagon
Technology Diffusion-Economic & Social Impact
Project results and key issues Milestone 4Alacramyn-Sales


Stage 4Developing Overseas market Alacramyn-NAMO Stage 5UA-UNAM-Silanes-Bioclon Collaboration for developing Anascorp. Milestone 5Anascorp FDA approval
Research team Paniagua-Alagon/Possanni & team Paniagua-Alagon/Possanni/ R. Stock & team Boyer (UA), Paniagua-Alagon/Possanni & team Boyer, Paniagua- Alagon-Possanni & team
Location Mexico City’s Health Secretary Cuernavaca campus UNAM’s IBT and Bioclon installations University of Arizona and Tucson Medical center University of Arizona and Tucson Medical center
Time required/Date ~ Date: 2000 ~ 7 years collaboration ~ 12 years collaboration 2011
Sales by year (MUSD estimated) ~ 5 Initially ~ 25 ~ 35 100
Formation of human resources PhD, MSc, Eng PhD, MSc, Eng PhD, MSc, Eng NA
Knowledge Prod. Int Art. +Patents (Scopus) Possani, Alagon Possani, Alagon US2005065331 (A1) Patent Antivenin Immunogens Possani, Alagon US2009142356 (A1) Patent “Orphan” drug FDA title


Figure 1. NAM-Silanes/Bioclon Alacramyn R&D+I Project life cycle roadmap

Tags: , , ,